The estimated Net Worth of Asset Management, Lp Chen B... is at least $4.1 Milion dollars as of 18 December 2020. Asset B owns over 800,000 units of BioAtla stock worth over $4,102,787 and over the last 4 years Asset sold BCAB stock worth over $0.
Sign up
Asset B BCAB stock SEC Form 4 insiders trading
Asset has made over 3 trades of the BioAtla stock since 2020, according to the Form 4 filled with the SEC. Most recently Asset bought 800,000 units of BCAB stock worth $14,400,000 on 18 December 2020.
The largest trade Asset's ever made was buying 800,000 units of BioAtla stock on 18 December 2020 worth over $14,400,000. On average, Asset trades about 463,333 units every 62 days since 2020. As of 18 December 2020 Asset still owns at least 2,292,060 units of BioAtla stock.
You can see the complete history of Asset B stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at BioAtla
Over the last 4 years, insiders at BioAtla have traded over $51,913,006 worth of BioAtla stock and bought 2,491,625 units worth $40,365,176 . The most active insiders traders include Guy Levy, Asset Management, Lp Chen B... oraz Jay M Phd Short. On average, BioAtla executives and independent directors trade stock every 25 days with the average trade being worth of $157,753. The most recent stock trade was executed by Sylvia Mcbrinn on 26 December 2023, trading 4,000 units of BCAB stock currently worth $9,320.
What does BioAtla do?
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
What does BioAtla's logo look like?
Complete history of Asset B stock trades at Avidity Biosciences, Akouos oraz BioAtla
BioAtla executives and stock owners
BioAtla executives and other stock owners filed with the SEC include:
-
Dr. Jay M. Short,
Co-Founder, CEO & Chairman -
Scott Andrew Smith,
Pres & Director -
Dr. Eric L. Sievers M.D.,
Chief Medical Officer -
Monica Sullivan,
Sr. VP of Intellectual Property & Contracts -
Christian Vasquez,
VP of Fin., Corp. Controller & Sec. -
Sheri Lydick,
Sr. VP of Commercial Strategy -
Dr. Eric L. Sievers,
Chief Medical Officer -
Dr. Cathy Chang Ph.D.,
Sr. VP of R&D -
Susie Melody,
VP of HR -
Lisa M. Pelton,
Accounting Mang. -
Philippe Martin,
Chief Clinical Devel. & Operations -
Richard A. Waldron,
Chief Financial Officer -
Lawrence Steinman,
-
Asset Management, Lp Chen B...,
-
Inc Pfizer Ventures (Us) Ll...,
-
Christian Vasquez,
See Remarks -
Jay M Phd Short,
Chief Executive Officer -
Richard A Waldron,
Chief Financial Officer -
Carolyn Anderson Short,
See Remarks -
Eric Sievers,
Chief Medical Officer -
Guy Levy,
-
Mary Ann Gray,
-
Susan Moran,
-
Parent Llc Himalaya,
10% owner -
Sylvia Mcbrinn,
-
Eddie Williams,